Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.9%

11 terminated/withdrawn out of 69 trials

Success Rate

60.7%

-25.8% vs industry average

Late-Stage Pipeline

6%

4 trials in Phase 3/4

Results Transparency

12%

2 of 17 completed trials have results

Key Signals

23 recruiting2 with results6 withdrawn

Enrollment Performance

Analytics

N/A
12(38.7%)
Phase 2
10(32.3%)
Phase 1
4(12.9%)
Phase 3
3(9.7%)
Early Phase 1
1(3.2%)
Phase 4
1(3.2%)
31Total
N/A(12)
Phase 2(10)
Phase 1(4)
Phase 3(3)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (69)

Showing 20 of 69 trials
NCT05174169Phase 2Recruiting

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Role: collaborator

NCT07565857Not ApplicableNot Yet Recruiting

Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

Role: lead

NCT06808880Recruiting

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

Role: lead

NCT07401316Not ApplicableRecruiting

Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

Role: collaborator

NCT07339384Not ApplicableNot Yet Recruiting

Signatera Assessment in Early-Stage Endometrial Cancer

Role: lead

NCT04920032Phase 1Recruiting

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Role: collaborator

NCT07214532Not ApplicableRecruiting

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Role: lead

NCT05108428Early Phase 1Active Not Recruiting

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Role: collaborator

NCT07502872Phase 2Not Yet Recruiting

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Role: collaborator

NCT04703101Phase 1Recruiting

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Role: collaborator

NCT04660344Phase 3Active Not Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

Role: collaborator

NCT04239703Recruiting

Trifecta-Kidney cfDNA-MMDx Study

Role: collaborator

NCT04707872Recruiting

Trifecta-Heart cfDNA-MMDx Study

Role: collaborator

NCT07021989Phase 2Not Yet Recruiting

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Role: collaborator

NCT05052671Recruiting

ctDNA Assay in Patients With Resectable Pancreatic Cancer

Role: collaborator

NCT05837663Recruiting

Trifecta-Lung cfDNA-MMDx Study

Role: collaborator

NCT06414603Not ApplicableActive Not Recruiting

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Role: lead

NCT07195071Not ApplicableRecruiting

Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening

Role: collaborator

NCT07292285Not Yet Recruiting

The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.

Role: collaborator

NCT07183319Phase 2Recruiting

Circulating Tumor DNA Response In Urothelial Cancer

Role: collaborator